Profiling bispecific T-cell engagers: Strategies for enhancing potency while minimizing cytokine release

Bergqvist P, Burke A, et al. Society for Immunotherapy of Cancer (SITC) Annual Meeting, November 2024

‍

This poster describes AbCellera’s T-cell engager (TCE) platform, including tailored design strategies to generate optimized TCEs. A panel of novel CD3-binding antibodies are used to widen the therapeutic window by generating TCEs with potent tumor cell-killing and optimal cytokine release. Efficacy of molecules may be enhanced by increasing T-cell activation and proliferation through costimulation of CD28 and 4-1BB. Finally, data is presented on the application of this platform to AbCellera’s B7-H4 and PSMA TCE programs, with preclinical characterization of TCEs showing tumor-cell killing and cytokine release profiles that are differentiated from clinical benchmarks.

‍‍